Historical rebound data shows average recovery of 9% within 30 trading days post similar declines, positioning upside toward $ Moderna's strategy in 2025 focuses on maintaining its COVID-19 immunization market share while advancing its late-stage candidate pipeline. Within respiratory vaccines, the company anticipates FDA approval for an expanded indication of its RSV vaccine. Furthermore, the company has submitted a combination influenza-COVID-19 vaccine for approval, supported by positive phase 3 study data. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103 [email protected] (844) 978-6257 Moderna stock price forecast shows potential momentum if WHO approves new vaccine formulations this quarter. Historical correlation with major biotech ETF (XBI) signals possible 5–7% upside, given recent ETF inflows of $450M.